Top Rosuvastatin Brands: A Curated Selection for Optimal Cholesterol Management

In recent years, rosuvastatin has become a go-to medication for managing cholesterol levels, leading many pharmaceutical companies to develop their own versions. Patients seeking reliable and effective options might find the sheer number of brands available a bit overwhelming. With each company offering unique formulations and competitive pricing, choosing the right brand can make all the difference in treatment outcomes. Below, we explore some of the top brands that stand out for their quality and effectiveness in rosuvastatin offerings.

Illustration of rosuvastatin

Best brands of rosuvastatin in 2025

Crestor

Crestor, the brand name for rosuvastatin, is a leading and highly potent statin medication, approved by the FDA in 2003, known for its efficacy in significantly reducing LDL cholesterol and increasing HDL cholesterol. It is particularly beneficial for patients who require aggressive management of high cholesterol levels, with studies showing it to be more effective than other statins like lovastatin and atorvastatin. Crestor was one of the top-selling medicines globally, with annual prescriptions surging to 24.8 million in 2015, and it accounted for a significant market share before its market exclusivity ended in 2016. Despite the decline in brand-name purchases post-exclusivity, generic rosuvastatin continues to be widely used, highlighting its enduring impact on the lipid-lowering market. The medication has been shown to be well-tolerated in clinical trials, with a low incidence of severe side effects. For a detailed comparison between lovastatin and Crestor, please visit the guide.

Sastin

Rosuvastatin, marketed under the brand name Crestor among others, is a highly effective statin produced by several manufacturers, including AstraZeneca, the original developer. It has been shown to reduce the risk of cardiovascular events and all-cause mortality more effectively than atorvastatin in some studies, boasting a 9% and 26% lower risk of all-cause mortality in two different databases. The rosuvastatin market is growing, with a projected market size of USD 655.99 million by 2031, increasing at a CAGR of 4.0% from 2023 to 2031. In 2022, the dyslipidemia segment accounted for the highest market share of 31.55% in the overall rosuvastatin market. Rosuvastatin is now available as a generic medication, making it more accessible.

Rosuless

Rosuvastatin, a potent statin, is predominantly produced by several key players, with AstraZeneca being a major manufacturer under the brand name Crestor. However, generic versions of rosuvastatin have gained significant traction, especially after the end of market exclusivity. For instance, in 2018, generic rosuvastatin purchases exceeded those of Crestor, reaching 22.5 million purchases. The global rosuvastatin market, driven by increasing incidences of cardiovascular diseases, is projected to grow at a CAGR of 4.0% from 2023 to 2031, with the market size expected to reach USD 655.99 million by 2031. North America, particularly the U.S., holds a significant market share, with the U.S. accounting for 66.15% of the North American market in 2022. More insights about the rosuvastatin market can be found in this detailed market report.

Roseday

Rosuvastatin, marketed under brands like Roseday, is a highly effective statin for reducing cholesterol levels, with studies showing it can lower LDL cholesterol by 31.2% to 61.2% and total cholesterol by 22.1% to 44.8% over a dose range of 1 to 80 mg/day. Rosuvastatin, including the Roseday brand, has gained significant market share due to its efficacy, with its use increasing notably in recent years. For instance, in 2022, rosuvastatin was the thirteenth most commonly prescribed medication in the United States, with over 37 million prescriptions. The drug's bioequivalence studies have been conducted in accordance with Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) standards, ensuring its quality and safety. The rising incidence of cardiovascular diseases further bolsters the demand for rosuvastatin, making it a crucial medication in the treatment of hypercholesterolemia. For more detailed information about rosuvastatin, visit the official RX List for Crestor.

Rosuvas

Rosuvastatin, a potent statin medication, is effectively produced by various manufacturers, with the market expected to grow significantly. For instance, the rosuvastatin market is projected to reach USD 655.99 million by 2031, growing at a CAGR of 4.0% from 2023 to 2031, driven by increasing incidences of cardiovascular diseases and high prevalence of dyslipidemia, which accounted for 31.55% of the market share in 2022. North America, particularly the U.S., holds a significant market share, with 66.15% in 2022, due to its well-established healthcare infrastructure. Rosuvastatin's efficacy in reducing cholesterol levels and cardiovascular events is highlighted by studies showing it may be more effective than atorvastatin in reducing all-cause mortality and cardiovascular events. The market is highly competitive, with several key players focusing on expanding their product offerings and market share.

Rovista

Rovista, a brand associated with several pharmaceutical companies, is a significant producer of rosuvastatin, a statin used to treat high cholesterol and prevent cardiovascular disease. In 2022, the global rosuvastatin market, which includes brands like Rovista, saw a record-high of over 37 million prescriptions in the United States alone. The market is expected to grow at a CAGR of 4.0% to 4.7% from 2023 to 2031, reaching a projected value of USD 655.99 million to USD 22.9 billion by 2031. North America, particularly the U.S., accounts for a significant market share, with the U.S. holding 66.15% of the North American market in 2022. Rovista's product is available in various forms, including capsules and tablets, and is distributed through hospital pharmacies, retail pharmacies, and online stores. For more details, you can refer to the rosuvastatin market analysis.

Rosutor

Rosuvastatin, marketed under the brand name Crestor among others, is a highly effective statin medication produced by renowned pharmaceutical companies like AstraZeneca. It is widely prescribed for its efficacy in reducing low-density lipoprotein (LDL) cholesterol, with studies showing it can lower LDL-C by up to 55% at an 80 mg dose. In 2022, it was the thirteenth most commonly prescribed medication in the United States, with over 37 million prescriptions. The drug has a bioavailability of 20% and an elimination half-life of approximately 19 hours. Its market is projected to grow significantly, reaching USD 22.9 billion by 2031, driven by the increasing incidence of cardiovascular diseases. For detailed information, you can refer to the FDA label for Rosuvastatin.

Rossuga

Rosuvastatin, particularly under brands like CRESTOR, is a highly effective statin produced by renowned manufacturers such as AstraZeneca. The drug has demonstrated dose-proportional pharmacokinetics across its various strengths, including 5, 10, 20, and 40 mg tablets, ensuring consistent efficacy. In 2022, rosuvastatin prescriptions in the U.S. reached a record high of over 37 million, highlighting its widespread use and trust in the medical community. The market for rosuvastatin is projected to grow significantly, with a CAGR of 4.7% from 2024 to 2031, reaching a market size of USD 22.9 billion by 2031. The drug's therapeutic doses, such as the 10 mg tablet, are particularly popular, with usage 36.1 times higher than the 5 mg dose in some regions. For more information, you can view the Crestor product monograph.

Cholstat

Rosuvastatin, marketed under brands like Crestor, is a highly effective statin produced by several manufacturers, though it is not specifically tied to a brand named "Cholstat." The rosuvastatin market is led by key players, with the drug commanding a substantial market share, accounting for 31.55% of the dyslipidemia segment in 2022. The market size for rosuvastatin was USD 463.85 million in 2022 and is projected to expand to USD 655.99 million by 2031, with a CAGR of 4.0% forecast during this period. North America, especially the U.S., holds the largest market share, accounting for 66.15% in 2022. The rising incidence of cardiovascular diseases and dyslipidemia is a significant driver for the increasing global demand for rosuvastatin. For more detailed insights into the market dynamics, visit the rosuvastatin market report.

Rosutec

Rosuvastatin, a crucial statin for managing high cholesterol and preventing cardiovascular diseases, is effectively produced by various manufacturers, including those under the Rosuvastatin brand. In 2022, the global rosuvastatin market size was valued at USD 463.85 million, with North America accounting for the highest market share at 35.15%. The market is expected to grow at a CAGR of 4.0% from 2023 to 2031, reaching USD 655.99 million by 2031. The high demand, driven by increasing incidences of cardiovascular diseases, makes rosuvastatin a significant product in the healthcare sector. For instance, in 2022, over 37 million prescriptions for rosuvastatin were issued in the United States alone.